文献速递心力衰竭与心肌病

急慢性心衰药物与器械评价的分层临床复合终点的开发与演进:20年视角

Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective.
PubMed 文献 · Circulation · 2016-01-01

传统心衰疗效评估存在局限,20年前开发的分层临床复合终点结合每次访视的症状评估与访视间的临床稳定性评价,按临床优先级排序而非加权计分。该终点可减少非完成患者偏倚,扩大贡献治疗差异的患者范围,已可靠区分有效与无效治疗,尤其适用于新器械、经导管介入及急性心衰新药评价。

要点

  • 分层临床复合终点按临床优先级排序,不采用任意加权数值评分。
  • 该终点减少非完成患者偏倚,扩大贡献治疗差异的患者范围。
  • 已可靠区分有效与无效治疗,尤其适用于器械和急性心衰药物评价。

核心结论

  • 分层临床复合终点可可靠区分有效与无效治疗,在慢性心衰新器械和经导管介入及急性心衰新药评价中可能具有特殊优势。

研究设计与样本

  • 本文为20年视角的方法学综述,阐述分层临床复合终点的开发背景、设计原理与演进。

主要发现

  • 传统固定时点评估单个组分或依赖与临床状态相关性差的替代生理指标存在局限。
  • 传统时间-事件试验过度加权次要临床事件,且对未发生事件患者的功能能力差异不敏感。
  • 分层临床复合终点结合每次访视的症状评估与访视间的临床稳定性评价,按临床优先级排序。
  • 该复合终点减少非完成患者偏倚,并扩大贡献治疗差异的患者范围。
  • 近期修改增强了其判别特征及准确评估新型心衰干预疗效的能力。

临床怎么用

  • 在慢性心衰新器械和经导管介入评价中可考虑使用分层临床复合终点。
  • 在急性心衰新药评价中可考虑使用分层临床复合终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditional approaches to the assessment of new treatments for heart failure have generally evaluated individual components of the syndrome at fixed points in time or have relied on surrogate physiological measures that are poorly correlated with the clinical status of patients. Conventional time-to-event trials that focus on morbidity and mortality represent an important methodological advance, but they generally assign undue weight to clinical events of less importance and are insensitive to difference in functional capacity among individuals who do not experience a clinical event during follow-up. Twenty years ago, a hierarchical clinical composite was developed to address these limitations; it aims to assess the clinical course of patients as a physician would in practice by combining a symptomatic assessment of the patient at each visit with an evaluation of the clinical stability of the patient between visits. The composite does not generate a numeric score by summing arbitrarily assigned weights to certain symptoms or events; instead, the composite ranks relevant measures and outcomes according to clinical priority. In doing so, the clinical composite minimizes the biases created by noncompleting patients in the assessment of symptoms or exercise tolerance while expanding the range of patients who contribute to the treatment difference in a typical morbidity and mortality trial. When applied appropriately, the hierarchical clinical composite end point has reliably distinguished effective from ineffective treatments. The composite may have particular advantages in the evaluation of new devices and transcatheter interventions in chronic heart failure and of new drugs for acute heart failure. Recent modifications enhance its discriminant characteristics and its ability to accurately assess the efficacy of novel interventions for heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer M. Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective. Circulation. 2016. PMID: 27881506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。